MTOR and cancer: VP-BEZ235, another autophagy inhibitor, is a novel and potent dual PI3K/mTOR inhibitor which results in anti-proliferative and anti-tumor activity in cancer cells [62]; it is currently in clinical trials for advanced solid tumors [63].